Annual report
4587.TEDINET S100T61M
Period2023-01-01 → 2023-12-31
Filed2024-03-28
StandardIFRS
ConsolidatedYes
Data checks18 of 22 passed
Amended by S100UF9P (2024-09-25).
Key figures · 162
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥28.7bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥9.0bn | 2022-01-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Ordinary income | ¥8.1bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.8bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥6.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥69.5bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥63.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥60.1bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total assets | ¥27.0bn | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥26.1bn | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥29.1bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥31.8bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥30.5bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥25.4bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥40.3bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥25.4bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥21.3bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥19.5bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥12.4bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥350m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥1.3bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.3bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥264m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥21.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥23.41 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥51.13 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.96 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥23.38 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥19.81 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥311.16 | at 2023-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥234.8 | at 2022-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥246.63 | at 2022-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥195.1 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 58.1% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 81.4% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.4% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 24.4% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 26.3% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 603 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 569 | at 2022-12-31 | Cons. | Number of employees |
| Employees | 141 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 128 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥12.7bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥15.4bn | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥11.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.0bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.2bn | 2018-01-01 → 2018-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥6.4bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Operating income | ¥9.1bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Ordinary income | ¥6.4bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.8bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥707m | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.8bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.0bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.9bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Net income | ¥5.8bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥4.3bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | ¥3.6bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥488m | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.8bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥68.2bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥55.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥26.6bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥26.3bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥17.8bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥20.0bn | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥27.6bn | at 2023-12-31 | Standalone | Liabilities |
| Total liabilities | ¥25.8bn | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.6bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥29.4bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥25.0bn | at 2021-12-31d | Standalone | Net assets |
| Net assets / equity | ¥21.2bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥17.0bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥17.4bn | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥16.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥847m | at 2022-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.0bn | at 2019-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.9bn | at 2018-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥242m | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.5bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥138m | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥237m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥29m | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥44.85 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.11 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.98 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.4 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.9 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.42 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.26 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.33 | 2018-01-01 → 2018-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥312.89 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥226.48 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥192.39 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥134.97 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥138.73 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 59.5% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.8% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.6% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 16.6% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.8% | 2022-01-01 → 2022-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.6% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.4% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2018-01-01 → 2018-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 130,010,400 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,910,400 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,310,400 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,310,400 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 153 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 155 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 141 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 128 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 107 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 104 | at 2018-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥87m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥87m |
| Drug Discovery And Development Businessreportable segment | employees | at 2023-12-31 | 153 pure |
| Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥12.7bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥12.7bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥6.4bn |
| Radiopharmaceuticals Businessreportable segment | employees | at 2023-12-31 | 450 pure |
| Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥16.1bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥16.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥87m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥475m |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥28.8bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥28.7bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥87m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥6.9bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-12-31 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-12-31 | −¥27m |
| Drug Discovery And Development Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥15.4bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥15.4bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥9.2bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥11.5bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥11.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥27m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥236m |
| —segment total | revenue | 2022-01-01 → 2022-12-31 | ¥26.9bn |
| —segment total | revenue external | 2022-01-01 → 2022-12-31 | ¥26.9bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥27m |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | ¥9.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,459
| Item | Context | Value | Unit |
|---|---|---|---|
| Retirement benefit liability ncl IFRS | CurrentYearInstant | 97647000 | JPY |
| Provisions ncl IFRS | Prior1YearInstant | － | JPY |
| Provisions ncl IFRS | CurrentYearInstant | 56120000 | JPY |
| Non current labilities IFRS | Prior1YearInstant | 20793330000 | JPY |
| Non current labilities IFRS | CurrentYearInstant | 20497214000 | JPY |
| Liabilities IFRS | Prior1YearInstant | 31823734000 | JPY |
| Liabilities IFRS | CurrentYearInstant | 29114303000 | JPY |
| Share capital IFRS | Prior1YearInstant | 3956738000 | JPY |
| Share capital IFRS | CurrentYearInstant | 3956738000 | JPY |
| Capital surplus IFRS | Prior1YearInstant | 4524436000 | JPY |
| Capital surplus IFRS | CurrentYearInstant | 4550372000 | JPY |
| Treasury shares IFRS | Prior1YearInstant | -607334000 | JPY |
| Treasury shares IFRS | CurrentYearInstant | -1085546000 | JPY |
| Retained earnings IFRS | Prior1YearInstant | 23848337000 | JPY |
| Retained earnings IFRS | CurrentYearInstant | 27804689000 | JPY |
| Other components of equity IFRS | Prior1YearInstant | 319287000 | JPY |
| Other components of equity IFRS | CurrentYearInstant | 5123456000 | JPY |
| Equity attributable to owners of parent IFRS | Prior1YearInstant | 32041465000 | JPY |
| Equity attributable to owners of parent IFRS | CurrentYearInstant | 40349709000 | JPY |
| Equity IFRS | Prior1YearInstant | 32041465000 | JPY |
| Equity IFRS | CurrentYearInstant | 40349709000 | JPY |
| Liabilities and equity IFRS | Prior1YearInstant | 63865200000 | JPY |
| Liabilities and equity IFRS | CurrentYearInstant | 69464013000 | JPY |
| Revenue IFRS | Prior1YearDuration | 26852430000 | JPY |
| Revenue IFRS | CurrentYearDuration | 28712194000 | JPY |
| Cost of sales IFRS | Prior1YearDuration | 8738942000 | JPY |
| Cost of sales IFRS | CurrentYearDuration | 11493476000 | JPY |
| Gross profit IFRS | Prior1YearDuration | 18113488000 | JPY |
| Gross profit IFRS | CurrentYearDuration | 17218717000 | JPY |
| Selling general and administrative expenses IFRS | Prior1YearDuration | 6220618000 | JPY |
| Selling general and administrative expenses IFRS | CurrentYearDuration | 7256195000 | JPY |
| Research and development expenditure recognized as expense during period IFRS | Prior1YearDuration | 2915118000 | JPY |
| Research and development expenditure recognized as expense during period IFRS | CurrentYearDuration | 3155366000 | JPY |
| Other income IFRS | Prior1YearDuration | 13517000 | JPY |
| Other income IFRS | CurrentYearDuration | 5084000 | JPY |
| Other expenses IFRS | Prior1YearDuration | 11073000 | JPY |
| Other expenses IFRS | CurrentYearDuration | 39192000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration | 8980196000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 6773047000 | JPY |
| Finance income IFRS | Prior1YearDuration | 189047000 | JPY |
| Finance income IFRS | CurrentYearDuration | 190981000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 2312643000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 2253012000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YearDuration | -203275000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration | -357547000 | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 6653325000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 4353469000 | JPY |
| Income tax expense IFRS | Prior1YearDuration | -901033000 | JPY |
| Income tax expense IFRS | CurrentYearDuration | 1317636000 | JPY |
| Profit loss IFRS | Prior1YearDuration | 7554358000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 18 of 22 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | mismatch |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | mismatch |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | mismatch |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | mismatch |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |